TAMIFLU (OSELTAMIVIR PHOSPHATE) MARKET ANALYSIS

Regional Analysis

Global Tamiflu (Oseltamivir Phosphate) Market- Regional Analysis

Among all regions, North America region is expected to dominate the market over the forecast period. This is attributed due to the North America hold 34.6% market share and increase in the storage of Tamiflu for the next influenza season North America region. For instance, on December 21, 2022, the U.S. government announced that the U.S. Department of Health and Human Services (HHS), in collaboration with Administration for Strategic Preparedness and Response (ASPR), are storing additional supply of Tamiflu available in order to respond to an increased demand for the antiviral during the flu season in the year 2022. This was achieved through Strategic National Stockpile (SNS). The government will work with their Assistant Secretary for Preparedness and Response (ASPR) Regional Teams, in order to evaluate any requests for Tamiflu through the SNS, thus ensuring that states, territories, and tribes receive the assistance they need without affecting the nation’s preparedness for a future pandemic flu.

Europe region is expected to be the second largest region over the forecast period. Due to increasing prevalence of seasonal influenza in Europe. For instance, according to the European Centre for Disease Prevention and Control (ECDC): 2022, estimated that the seasonal influenza causes 4 to 5 million symptomatic infections in the European Union every year and 15,000 to 7,000 European citizens die because of the causes associated with influenza.

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC Countries, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa